NASDAQ:BTMD - Nasdaq - US0906831039 - Common Stock - Currency: USD
4.26
+0.05 (+1.19%)
The current stock price of BTMD is 4.26 USD. In the past month the price decreased by -11.43%. In the past year, price decreased by -24.47%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 66.89 | 824.51B | ||
JNJ | JOHNSON & JOHNSON | 16.69 | 401.33B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 26.18 | 386.95B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 21.41 | 240.28B | ||
MRK | MERCK & CO. INC. | 12.39 | 239.09B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 14.56 | 228.26B | ||
PFE | PFIZER INC | 8.59 | 151.49B | ||
SNY | SANOFI-ADR | 14.24 | 148.55B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 53.59 | 123.97B | ||
GSK | GSK PLC-SPON ADR | 8.29 | 81.62B | ||
ZTS | ZOETIS INC | 28.78 | 76.29B | ||
TAK | TAKEDA PHARMACEUTIC-SP ADR | 33.71 | 47.88B |
biote Corp. is a woman-led company, which engages in providing bio identical hormone pellet therapy. The company is headquartered in Irving, Texas and currently employs 194 full-time employees. The company went IPO on 2021-03-02. The firm provides the necessary components to enable Biote-certified practitioners to establish, build and implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The Biote Method is a comprehensive, end-to-end practice building platform that provides Biote-certified practitioners with the components specifically developed for practitioners in the hormone optimization space: Biote Method education, training and certification, practice management software, inventory management software, and information regarding available hormone replacement therapy (HRT) products, as well as digital and point-of-care marketing support. The company also sells a complementary Biote-branded line of dietary supplements. The Biote Method’s proprietary clinical decision support (CDS) software assists physicians in establishing individualized dosing for patients.
BIOTE CORP -A
1875 W. Walnut Hill Ln #100, Floor 5
Irving TEXAS US
Employees: 194
Company Website: https://haymakeracquisition.com/
Investor Relations: https://ir.biote.com/
Phone: 19724869346
The current stock price of BTMD is 4.26 USD. The price increased by 1.19% in the last trading session.
The exchange symbol of BIOTE CORP -A is BTMD and it is listed on the Nasdaq exchange.
BTMD stock is listed on the Nasdaq exchange.
12 analysts have analysed BTMD and the average price target is 10.15 USD. This implies a price increase of 138.16% is expected in the next year compared to the current price of 4.26. Check the BIOTE CORP -A stock analysts ratings, price target forecast and up-and down grades for more detailed information.
BIOTE CORP -A (BTMD) has a market capitalization of 231.49M USD. This makes BTMD a Micro Cap stock.
BIOTE CORP -A (BTMD) currently has 194 employees.
BIOTE CORP -A (BTMD) has a resistance level at 4.27. Check the full technical report for a detailed analysis of BTMD support and resistance levels.
The Revenue of BIOTE CORP -A (BTMD) is expected to grow by 7.02% in the next year. Check the estimates tab for more information on the BTMD EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
BTMD does not pay a dividend.
BIOTE CORP -A (BTMD) will report earnings on 2025-03-12, after the market close.
The PE ratio for BIOTE CORP -A (BTMD) is 14.2. This is based on the reported non-GAAP earnings per share of 0.3 and the current share price of 4.26 USD. Check the full fundamental report for a full analysis of the valuation metrics for BTMD.
The outstanding short interest for BIOTE CORP -A (BTMD) is 2.88% of its float. Check the ownership tab for more information on the BTMD short interest.
ChartMill assigns a fundamental rating of 6 / 10 to BTMD. Both the profitability and the financial health of BTMD get a neutral evaluation. Nothing too spectacular is happening here.
Over the last trailing twelve months BTMD reported a non-GAAP Earnings per Share(EPS) of 0.3. The EPS increased by 236.36% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 2.13% | ||
ROA | 5.05% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 83% to BTMD. The Buy consensus is the average rating of analysts ratings from 12 analysts.
For the next year, analysts expect an EPS growth of 174.18% and a revenue growth 7.02% for BTMD